044 209 91 25 079 869 90 44
Merkliste
Die Merkliste ist leer.
Der Warenkorb ist leer.
Kostenloser Versand möglich
Kostenloser Versand möglich
Bitte warten - die Druckansicht der Seite wird vorbereitet.
Der Druckdialog öffnet sich, sobald die Seite vollständig geladen wurde.
Sollte die Druckvorschau unvollständig sein, bitte schliessen und "Erneut drucken" wählen.

Macrolides as Immunomodulatory Agents

E-BookPDFE-Book
Verkaufsrang1166inMedizin
CHF189.00

Beschreibung

For over 50 years, clinicians have known that macrolide antibiotics have effects on inflammation and the immune system that are not related to their antimicrobial properties. These immunomodulatory properties, best described for treating inflammatory airway diseases, protect the lung and the host and improve clinical status. 



This book summarizes our current knowledge regarding proposed mechanisms for these properties, established clinical results, and what the future may hold with emphasis on novel clinical applications and the fascinating development of non-antimicrobial macrolides with preserved and enhanced immunomodulatory properties.â
Weitere Beschreibungen

Details

Weitere ISBN/GTIN9783031428593
ProduktartE-Book
EinbandE-Book
FormatPDF
Format HinweisWasserzeichen
Erscheinungsdatum04.01.2024
Auflage1st ed. 2024
ReiheProgress in Inflammation Research
Reihen-Nr.92
Seiten287 Seiten
SpracheEnglisch
IllustrationenVIII, 287 p. 18 illus., 10 illus. in color.
Artikel-Nr.11707331
KatalogVC
Datenquelle-Nr.5684080
WarengruppeMedizin
Weitere Details

Reihe

Über den/die AutorIn

Professor Bruce K. Rubin is the Jessie Ball duPont Distinguished Professor of Pediatrics and Biomedical Engineering at Virginia Commonwealth University. He trained in Biomedical Engineering at Oxford University on a Rhodes Scholarship and in Paediatric Respirology in Toronto. He holds the MD and MEngr degrees from Tulane and an MBA degree from Wake Forest University.

Prof. Rubin received the Forest Bird Lifetime Scientific Achievement Award and the Jimmy A Young Medal from the American Association for Respiratory Care, and he is a Prix Galien Laurate. He holds appointments in four medical schools, is on the editorial board of 10 journals, has published more than 300 original research papers and chapters (H-index 74) and holds 10 patents. His research focus is regulation of mucus clearance in health and disease, airway inflammation and immunomodulation, and aerosol delivery of medications. 

Dr. Rubin is also a magician, a member of the International Brotherhood of Magicians (Wizard Award) and over the past 30 years has taught medical magic in 43 countries on 5 continents.






Dr. Masaharu Shinkai is the Vice Director of Tokyo Shinagawa Hospital and also the Director of the Clinical Trial Development & Research Center. He holds the MD from National Defense Medical College and a PhD degree from Yokohama City University. He has been involved in many respiratory clinical trials and drug development in Japan. In the last five years, he has been the principal investigator in 35 clinical trials, 22 of which have achieved FPI (First Patient In). He has about 100 articles on PubMed. Most recently, he has published 24 clinical and immunological papers on COVID-19 and its vaccines. His research focus is homeostasis, immunomodulation and mucus regulation in airway inflammation.